A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk
Project Number1R61DA062217-01
Contact PI/Project LeaderBAGLEY, SARAH M Other PIs
Awardee OrganizationBOSTON MEDICAL CENTER
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
Between 2015 and 2019, overdose deaths translated to 1.25 million years of life lost among adolescents and
young adults (“youth”), and the percent change in fatal overdose death rates among adolescents was higher
than adults between 2019 and 2020. Similar to adults, illicitly manufactured fentanyl (IMF) is the major driver of
drug overdose deaths in youth. Unlike adults, youth are more commonly exposed to IMF through counterfeit
pills, and some youth are unaware that they are using a pill that is counterfeit and thus unintentionally exposed
to IMF. Unfortunately, any youth who uses a counterfeit pill or other drug is at risk for an overdose, even after
first use. There is an urgent need for evidence-based overdose prevention interventions for youth. Within the
healthcare setting, youth primary care providers routinely provide injury prevention anticipatory guidance as
part of annual comprehensive physical exams and are well positioned to provide anticipatory guidance for
overdose prevention. Through this R61/R33 mechanism we propose to develop and evaluate the efficacy of an
universal overdose prevention intervention that will increase: (1) awareness of the risks of fentanyl and other
emerging drugs in the drug supply, (2) knowledge of strategies to reduce overdose risk, and (3) recognition
and response to overdose. In the R61, in collaboration with our existing Youth Community Advisory Board, we
proposed to use the Informational-Motivational-Behavioral Skills Model to develop an overdose prevention
intervention to be delivered in primary care setting. We will pilot the intervention in two primary care settings at
Boston Medical Center, Pediatric Primary Care and Family Medicine, to assess acceptability and feasibility for
providers and youth ages 13 to 26 years who are being seen for an annual comprehensive physical exam. We
will do this through a pilot two-arm cluster randomized controlled trial (RCT) that is randomized at the provider
level. During the pilot trial, we will share preliminary data with the Community Advisory Board to inform any
needed adaptations to the intervention. If the intervention is acceptable and feasible to providers we will
transition to evaluating the intervention’s efficacy in a larger RCT during the R33. In the R33, we will again
conduct a two-arm cluster RCT randomized at the provider level using the same inclusion/exclusion criteria,
procedures, and study measures as the R61. Youth outcomes will be evaluated at one-year follow up and the
primary outcome will be youth knowledge of the risk associated with fentanyl and other emerging drugs in the
drug supply. Secondary outcomes will include youth knowledge of strategies to reduce overdose risk,
recognize and respond to an overdose. If the universal youth overdose prevention intervention is effective this
will benefit youth and public health generally as youth will be better prepared to decrease their risk for
overdose, and recognize and respond to others who have an overdose.
Public Health Relevance Statement
PROJECT NARRATIVE
There is an urgent need to develop an effective universal overdose prevention intervention for youth given
rising overdose deaths for youth, and the risks associated with fentanyl and other emerging drugs in the drug
supply. Primary care providers provide anticipatory guidance for injury prevention to youth as part of annual
physical exams and are therefore well positioned to deliver a universal overdose prevention intervention. An
effective universal overdose prevention intervention will directly benefit youth by decreasing their risk, and will
benefit public health generally as they will be more prepared to recognize and respond to others who have an
overdose.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAdolescentAdolescent Risk BehaviorAdolescent and Young AdultAdultAgeAwarenessBehavioralBenzodiazepinesBostonCessation of lifeChildhoodCollaborationsCommunitiesConduct Clinical TrialsControl GroupsCounselingDataDeath RateDevelopmentDrowningDrug usageEnsureExclusion CriteriaExposure toFamilyFamily PracticeFentanylFirearmsHealth BenefitHealth PersonnelHomeIndividualInjuryInterventionKnowledgeLearningMeasuresMedical centerModelingMotivationNaloxoneOutcomeOverdoseOverdose reductionPharmaceutical PreparationsPositioning AttributePreventionPrevention educationPrimary CareProceduresProviderPublic HealthRandomizedRandomized, Controlled TrialsReadinessRecommendationRecording of previous eventsRiskRisk ReductionSafetyScienceStimulantTestingTimeTranslatingTreatment EfficacyTrustUnited StatesYouthacceptability and feasibilityadolescent substance useagedarmcommunity advisory boardcommunity engagementcost effectivedesignefficacy evaluationevidence baseexperiencefollow-upgroup interventionhealth care settingsimprovedinjury preventionmanufacturenovelopioid useoverdose deathoverdose preventionoverdose riskpediatricianpillpilot trialpolysubstance usepreventive interventionprimary care providerprimary care settingprimary outcomerandomized trialresponsesecondary outcomeskillsstandard of caretherapy developmenttrial designyears of life lost
No Sub Projects information available for 1R61DA062217-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R61DA062217-01
Patents
No Patents information available for 1R61DA062217-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R61DA062217-01
Clinical Studies
No Clinical Studies information available for 1R61DA062217-01
News and More
Related News Releases
No news release information available for 1R61DA062217-01
History
No Historical information available for 1R61DA062217-01
Similar Projects
No Similar Projects information available for 1R61DA062217-01